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Preventing and Controlling Tuberculosis
Along the U.S.-Mexico Border
Work Group Report
Summary
Converging factors contribute to elevated tuberculosis (TB) incidence and
complicate case management in the U.S. states bordering Mexico. These factors
include a) Mexico’s higher TB rate; b) low socioeconomic status and limited access
to health care in the border area; c) frequent border crossings and travel in the
United States for employment, commerce, health services, and leisure; d)
language and sociocultural differences; and e) lack of coordinated care across
health jurisdictions on both sides of the U.S.-Mexico border. Prevention and
control efforts that address the challenges created by border-crossing
populations require collaboration among local, state, and national TB control
programs in both countries. In June 1999, to facilitate future discussions with
Mexican counterparts, CDC convened a meeting of TB control officials from the
four U.S. states bordering Mexico (i.e., California, Arizona, New Mexico, and
Texas) to address TB prevention and control in the border area. Focus areas
included a) surveillance needs, b) case management and therapy completion, c)
performance indicators and program evaluation, and d) research needs. Meeting
participants’ deliberations and resulting proposals for action by CDC and state and
local TB control programs are detailed in this report.
INTRODUCTION
During 1994–1998, approximately 3.9 million legal immigrants entered the United
States. Of those immigrants, 16.5% were from Mexico, the leading country of birth for all
legal immigrants, and 5% were from seven countries in Central America (1 ). Addition-
ally, an estimated 2.7 million persons from Mexico and Central America live in the United
States without documentation of citizenship or visas (2 ). Persons from these countries
contribute substantially to U.S. tuberculosis (TB) morbidity.
TB disease among foreign-born persons living in the United States is increasing. In
1999, 43% (7,553) of the 17,531 TB cases reported in the United States were among
foreign-born persons, compared with 24% (6,262) of the 25,701 cases reported in 1990.
In 1999, Mexico was the country of origin for 23% (1,753) of all foreign-born persons with
TB. Of TB cases among Mexican-born persons, three fourths were reported from the four
U.S. states bordering Mexico: California, 820 cases; Texas, 364 cases; Arizona, 67 cases;
and New Mexico, 17 cases (3 ). In 1999, TB cases among Mexican-born persons repre-
sented approximately 25% of all reported TB in the four border states. Incidence of TB
was higher for the majority of border counties than the national TB rate.
TB is brought into the United States from Mexico and Central America in three ways:
a) persons with active TB disease move northward across the border; b) persons with
latent TB infection experience active disease after arrival in the United States; or c) U.S.
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residents touring Mexico, including immigrants, acquire TB disease after returning to the
United States (4–7 ). After a person with TB enters the United States, further transmis-
sion might occur, which contributes to TB morbidity in the United States directly from
source patients and indirectly from their contacts.
Converging factors contribute to elevated TB incidence and complicate TB control
efforts along the U.S.-Mexico border. Mexico’s higher TB rate of approximately 27 cases/
100,000 population, compared with that of the United States, and the migratory flow
across the border result in elevated TB incidence in the geographic areas most affected
by cross-border immigration. Low socioeconomic status, crowded living conditions, and
limited access to health care increase the risk for TB transmission on both sides of the
border. Frequent bilateral border crossings and movement within the United States
contribute to delays in TB diagnosis and impede treatment completion. Language and
sociocultural differences also contribute to delays in seeking care and influence adher-
ence to treatment (8,9 ). Coordinating TB case management across an international
border is complicated, and among certain TB patients, outcomes are compromised.
Ultimately, lowering TB rates in the border area and reducing racial and ethnic dis-
parities of TB disease depend on identifying and treating infected persons on both sides
of the border until patients are cured. Therefore, TB prevention and control efforts along
the U.S.-Mexico border require the cooperation of local, state, and national TB control
programs in both countries, including strategies for coordinated interventions and fund-
ing to ensure that adequate resources are available (Box).
To begin addressing this public health problem, the TB Along the U.S.-Mexico Border
Work Group was formed. In June 1999, staff of CDC’s National Center for HIV, STD, and
TB Prevention/Division of Tuberculosis Elimination convened a meeting of TB control
officials from Arizona, California, New Mexico, and Texas to develop a coordinated
domestic strategy. After reviewing the epidemiology of the TB epidemic from national
and local perspectives, the work group focused on a) surveillance needs, b) case man-
agement and therapy completion, c) performance indicators and program evaluation,
and d) research needs. For each of these topics, the participants identified key problems,
objectives, and resources needed to enhance TB prevention and control efforts along the
border. The following programmatic actions for federal agencies and state and local TB
control programs were then identified:
• establishing a consensus case definition for a binational TB case and assessing
the need for a registry of binational cases;
• improving the clinical care of binational TB patients and their close contacts in the
border states by expanding existing activities and developing new programs for
TB diagnosis and case management to ensure treatment completion;
• creating evaluation tools for TB prevention and control efforts, including contact
investigations and targeted testing of populations at high risk; and
• setting research priorities.
This report contains the work group’s proposals regarding these programmatic
actions. These proposals are not CDC directives, but they should be regarded as a start-
ing point for public health practice and TB prevention and control interventions.





In 1991, the Texas Department of Health
established three projects to provide case
management for TB patients and their
contacts who live or work in both the
United States and Mexico. Projects include
Project Juntos (serving El Paso-Ciudad
Juarez and Las Cruces, New Mexico, West
Texas, and Ojinaga in Chihuahua); Los Dos
Laredos (Laredo-Nuevo Laredo area); and
Grupo Sin Fronteras (lower Rio Grande
Valley, including the Brownsville-Harlingen-
McAllen area in Texas and the Matamoros-
Reynosa area in Mexico). The three
projects managed 884 binational TB
patients and their contacts through 1998
and continue to provide laboratory support
for diagnosis and case management
through cooperative relationships among
TB control programs on both sides of the
border.
BOX. Selected cooperative tuberculosis (TB) control activities along the U.S.-Mexico
border, including binational projects, case-referral systems, and initiatives for TB
surveillance and laboratory training
Three cross-border projects were estab-
lished in 1996 by Arizona Department of
Health Services in collaboration with the
Sonora, Mexico, state health department.
Serving Santa Cruz County-Nogales,
Cochise County-Agua Prieta, and Yuma
County-San Luis Rio Colorado, the projects
monitor multidrug-resistant TB, provide
directly observed therapy, conduct
outreach for patients who have missed
clinic visits and who frequently travel
across the border, and provide Sonora with
support from the Arizona State Laboratory
Services.
Since the mid-1980s, representatives from
public and private TB control programs in
San Diego, Los Angeles, and Imperial
Counties, and Baja California Norte have
been discussing management of binational
cases, planning joint activities (e.g.,
binational training), providing outreach to
practitioners and pharmacists, developing
educational materials, and conducting
media campaigns.
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BOX. (Continued) Selected cooperative tuberculosis (TB) control activities along the U.S.-
Mexico border, including binational projects, case-referral systems, and initiatives for TB




TB Net Based in Austin, Texas, and operated by
the Migrant Clinicians Network,* TB Net
assists persons who have difficulty
gaining access to medical services and
facilitates coordinated treatment by
multiple providers. The program provides
patients with a portable medical record and
referrals to nearby TB clinics and provides
health-care practitioners with a centralized
repository of medical information. During
1996–March 2000, TB Net assisted 139
persons with active TB disease and 522
persons with latent TB infection.
* Information regarding the Migrant Clinicians Network is available at <http://
www.migrantclinician.org> (accessed November 21, 2000).
Two annual events, a farm worker health
information fair in Calexico, California, and
a binational TB symposium for health-care
personnel in Mexicali, Baja California Norte,
provide information regarding TB, tubercu-
lin skin testing, and other health screen-
ings. A binational TB social marketing
campaign focuses on recognizing TB
symptoms and encourages early evalua-
tion through radio and television an-
nouncements and billboards in the
Imperial and Mexicali Valleys.
CURE-TB, operated by the San Diego
County TB control program since 1994, is a
joint U.S.-Mexico referral system designed
to improve the continuity of care for
patients with active TB disease and their
contacts who are at high risk. The project
provides education and assistance to
patients who move between Mexico and
the United States during the course of
their treatment. The system also notifies
providers in both countries of a patient’s
arrival in their communities and facilitates
the exchange of patients’ clinical informa-
tion. During 1997–2000, CURE-TB referred
250 active TB patients and 372 contacts for
testing and treatment. In 1999, 80% of the
active TB patients referred had completed
or continued their treatment.
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As part of CDC’s genotyping and surveil-
lance network since 1996, TB control
programs in Cameron and Hidalgo Coun-
ties in the lower Rio Grande Valley of Texas
and in the Dallas-Tarrant County metropoli-
tan area interview all patients with culture-
positive TB and submit specimens for DNA
(deoxyribonucleic acid) fingerprinting.
Organized in 1996 by health officers from
the four U.S. and six Mexican border states
and representatives from nongovernmental
organizations, Ten Against TB is designed
to strengthen binational collaboration,
enhance laboratory capacity, improve and
coordinate epidemiologic studies, optimize
case management, and promote public and




U.S.-Mexico Border TB Laboratorian
Binational Training Project
Other Organizations
In collaboration with Mexico’s national
public health laboratory program, CDC and
the Association of Public Health Laborato-
ries provide training in the border area.
Participants include staff from the six
Mexican border states, four U.S. border
states, and the National Laboratory
Training Network. In addition to providing
training in culture methods, CDC and
Mexico are collaborating on national
proficiency testing for >500 laboratories
that perform acid-fast bacilli microscopy in
Mexico’s Secretaria de Salud system. That
program involves onsite assessment
combined with slide proficiency tests to
determine technical ability.
The U.S. Health Resources and Services
Administration, the Pan American Health
Organizaiton, the U.S.-Mexico Border
Health Association, the U.S.-Mexico
Binational Commission, the U.S.-Mexico
Border Health Commission, the Border XXI
Program, state and local health depart-
ments, and universities collaborate on
diverse projects to enhance TB control
efforts along the U.S.-Mexico border.
BOX. (Continued) Selected cooperative tuberculosis (TB) control activities along the U.S.-
Mexico border, including binational projects, case-referral systems, and initiatives for TB
surveillance and laboratory training
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FIGURE 1. U.S.-Mexico border states
BACKGROUND
Geographic Characteristics of the U.S.-Mexico Border
The U.S.-Mexico border is approximately 2,000 miles long and separates four U.S.
states — California, Arizona, New Mexico, and Texas — from six Mexican states — Baja
California Norte, Sonora, Chihuahua, Coahuila, Nuevo León, and Tamaulipas (Figure 1).
Approximately 1 million persons cross the U.S.-Mexico border daily. Major metropolitan
areas straddle the border, including San Diego-Tijuana (population: 4 million persons), El
Paso-Ciudad Juarez (1.9 million), Laredo-Nuevo Laredo (0.4 million), Brownsville-
Matamoros (0.5 million), and Harlingen/McAllen-Reynosa (1 million). Two of these areas,
San Diego-Tijuana and El Paso-Ciudad Juarez, account for 40% of daily border crossings.
Although they are legally separate cities, these sister cities have become closely inte-
grated binational and bicultural communities by sharing social, environmental, and eco-
nomic interests and problems.
Counties along the U.S.-Mexico border are among the poorest economically in the
United States. Approximately one third of U.S. border families live at or below the pov-
erty line compared with a national average of 11% (10,11 ). An estimated 400,000 per-
sons live in the United States along the Texas border in colonias  (i.e., semirural
communities) without access to public drinking water or wastewater systems. Unem-
ployment rates in the border area are approximately threefold higher than those in the
rest of the United States. A total of 10 of 24 counties evaluated along the U.S.-Mexico
border are medically underserved and of low socioeconomic status (12 ). During 1990–
1996, communicable diseases other than TB (i.e., brucellosis, measles, hepatitis A, hepa-
titis B, mumps, pertussis, salmonellosis, and shigellosis) occurred at higher rates in U.S.
Tamaulipas
US-Mexico border area
    Four U.S. states
    Six Mexican states
    ~2,000 miles long
    ~9 million population
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border counties than in nonborder counties (13 ). Diabetes, which increases the risk for
TB, is also more common among Hispanics and American Indians compared with non-
Hispanic whites (14 ).
TB Rates in the Border Area
TB rates among border communities are higher than the rates for their respective
states overall (Figure 2, Table 1). During 1998–1999, the average TB rates/100,000 popu-
lation were 22.9 in Laredo and 39.7 in Nuevo Laredo, compared with 8.7 in Texas and
33.1 in Tamaulipas. Rates in other border-city pairs were 21.8 in Brownsville and 70.3 in
Matamoros; 15.1 in McAllen and 43.9 in Reynosa; and 10.1 in El Paso and 17.8 in Ciudad
Juarez (Eugene J. Tamames, Texas Department of Health, personal communication,
July 2000). The TB rate in San Diego County was 10.3/100,000 population, but among
Hispanics of predominately Mexican descent, the rate was 23.5 cases/100,000 popula-
tion, higher than the state rate of 12.9 for Hispanics (Reuben M. Granich, M.D., M.P.H.,
California Department of Health Services, personal communication, July 2000). A 1998
tuberculin testing program in one San Diego County school district identified a 32% skin-
test–positive rate among Mexican-born high school students (15 ).
Overall TB incidence is higher in Mexico than in the United States. The 1999 incidence
of pulmonary TB in Mexico was 17 cases/100,000 population nationally and 27.1 cases/
100,000 population along the U.S.-Mexico border (Elizabeth Ferreira, M.D., Mycobacte-
rium Prevention and Control Program of Mexico, personal communication, July 2000).
Adjusting for underreporting, the World Health Organization estimates the incidence of
pulmonary TB in Mexico to be 45 cases/100,000 (16 ).
Prevalence of drug-resistant TB strains increases concerns regarding the cross-
border spread of TB. In 1997, CDC and the Secretariat of Health of Mexico conducted a
population-based survey to gather data regarding TB drug resistance for the three Mexi-
can states of Baja California Norte, Sinaloa, and Oaxaca (17 ). In those Mexican states,
drug-resistance rates for >1 of the first-line drugs (i.e., isoniazid, rifampin, or pyrazina-
mide) used among new and retreatment patients with sputum-smear–positive pulmo-
nary TB were 13% and 51%, respectively. However, one study demonstrated that limiting
drug-resistance surveillance to acid-fast bacilli smear-positive cases might underesti-
mate the rate of primary drug resistance in Mexico (18 ). Similarly, retreatment patients
were more likely than new patients to have isolates of multidrug-resistant TB (i.e., resis-
tance to isoniazid and rifampin) (2.4% and 22%, respectively). In 1997, in contrast, 1.4%
of culture-positive patients in the United States had multidrug-resistant TB (19 ).
Characteristics of TB Cases Reported from U.S. States
Bordering Mexico*
During 1993–1998, the four border states reported to CDC a total of 8,661 TB cases
among Mexican-born persons. The proportion of TB cases among Mexican-born persons
from counties bordering Mexico was similar for Arizona (43%), New Mexico (41%), and
Texas (42%); however, the proportion was substantially lower for California (14%). A
higher proportion of cases were among Mexican-born persons aged 15–44 years; other-
wise, characteristics were similar between Mexican-born and U.S.-born TB patients
(Table 2).
* Unless otherwise noted, information in this section is based on national TB surveillance
data reported by state programs to CDC’s Division of Tuberculosis Elimination.
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TABLE 1. Tuberculosis (TB) rates and proportion of cases among Hispanic and Mexican-
born persons in states and border counties — California* and Texas,† 1998
California Texas§
border border
Characteristic United States§ California§ Texas counties¶ counties**
Percentage of U.S. TB cases — 21 10 2.1 1.7
TB case rate/100,000 population 6.8 11.8 9.2 13.0 16.8
TB cases among Hispanics (%) 22 36 48 56 94
TB case-patients born in Mexico (%) 10 22 22 35 49
* California border counties include Imperial and San Diego.
† Texas border counties include Brewster, Cameron, El Paso, Hidalgo, Hudspeth, Jeff Davis, Kinney, Maverick,
Presidio, Starr, Terrell, Val Verde, Webb, and Zapata.
§ Source: CDC. Reported tuberculosis in the United States, 1998. Atlanta, GA: US Department of Health and
Human Services, CDC, National Center for HIV, TB, and STD Prevention; August 1999. Available at <http://
www.cdc.gov/nchstp/tb>. Accessed November 1, 2000.
¶ Source: California Department of Health Services, unpublished data, 1998.
** Source: Texas Department of Health, unpublished data, 1998.
FIGURE 2. Tuberculosis (TB) rates in U.S. states and counties* bordering Mexico, 1998
* Only border counties with 10 TB cases/100.000 were included.



















Vol. 50 / No. RR-1 MMWR 9
TABLE 2. Tuberculosis (TB) cases reported to CDC from Arizona, California, New Mexico,
and Texas, 1993–1998*
Mexican-born TB patients U.S.-born TB patients
Characteristic Number % Number %
Sex 8,661 — 19,351 —
Male 5,580 64.4 13,128 67.8
Female 3,078 35.5 6,211 32.1
Age (years)
0–14 677 7.8 2,441 12.6
15–24 1,291 14.9 1,126 5.8
25–44 3,450 39.8 6,814 35.2
45–64 1,908 22.0 5,165 26.7
>65 1,334 15.4 3,801 19.6
Site of disease
Pulmonary 6,572 75.9 14,800 76.5
Extrapulmonary 1,410 16.3 2,984 15.4
Both 677 7.8 1,554 8.0
Sputum bacteriology† 6,740 — 14,497 —
Smear positive 3,456 51.3 6,664 46.0
Culture positive 5,074 75.3 10,848 74.8
Chest radiograph§ 7,249 — 16,354 —
Normal 141 2.0 510 3.1
Abnormal 6,962 96.0 14,989 91.7
Noncavitary 4,550 65.4 9,335 62.3
Cavitary 1,994 28.6 3,777 25.2
Human immunodeficiency virus
status among TB patients
aged 25–44 years¶ 3,450 — 6,814 —
Positive 515 14.9 2,166 31.8
Negative 324 9.4 862 12.7
Unknown 2,611 75.7 3,786 55.6
Reason therapy was stopped** 7,130 — 16,039 —
Patient completed therapy 5,622 78.9 12,344 77.0
Patient died 429 6.0 1,878 11.7
Patient moved 624 8.8 643 4.0
Patient could no longer be located 281 3.9 654 4.1
Other 174 2.4 520 3.2
* Numbers might not total 100% because of missing or unknown data.
† Among adults aged >15 years with pulmonary TB only.
§ Chest radiographs for pulmonary TB patients only.
¶ Positive human immunodeficiency virus status only was reported for TB patients from
California; these data were generated by matching TB and acquired immunodeficiency
syndrome registries.
**Among patients who were alive at diagnosis and treated with an initial drug regimen of >1
drugs, 1993–1997.
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Data reported to CDC during 1993–1998 confirm higher drug-resistance rates among
Mexican-born TB patients than among U.S.-born TB patients. Ninety five percent (5,756)
of reported culture-positive TB cases among Mexican-born persons and 92% (12,969) of
cases among U.S.-born persons without a previous history of TB had initial drug-
susceptibility test results for isoniazid and rifampin. Of these, 9.1% of initial isolates from
Mexican-born persons and 4.4% of those from U.S.-born persons were resistant to iso-
niazid at least; 1.4% of initial isolates from Mexican-born persons and 0.6% of isolates
from U.S.-born persons were multidrug-resistant TB.
During 1993–1998, date of arrival in the United States was reported for 89% of TB
cases among foreign-born persons from the four border states. Approximately 54% of
Mexican-born TB patients resided in the United States for >5 years before their TB was
diagnosed; 14% of Mexican-born TB patients had lived in the United States for <1 year
before their TB was diagnosed.
During 1995–1997, a study was conducted of TB cases reported among foreign-born
Hispanics from eight U.S. counties bordering Mexico and seven urban nonborder coun-
ties in the four border states (20 ). Results from that study regarding the migration prac-
tices of TB patients in the border area demonstrated that, compared with patients from
nonborder counties, foreign-born Hispanic TB patients
• had lived in the United States longer (17 versus 11 years);
• more often had immigrated from Mexican border communities (62% versus
25%);
• more often had returned to Mexico weekly (38% versus 2%) or during the past
12 months (72% versus 47%); and
• more often had been born in Mexico (94% versus 80%).
SURVEILLANCE NEEDS
To better understand the epidemiology of TB cases along the U.S.-Mexico border,
surveillance needs (e.g., development of a case definition and TB registry for binational
cases) should be addressed.
Case Definition
No standard surveillance definition for a binational TB case is in use by border TB
control programs; thus, using a uniform case definition would enable standardized data
collection and increase accuracy in data analysis and comparison. A standardized case
definition should be flexible enough to encompass all factors related to binational TB
patients and the health providers who serve them, yet specific enough to facilitate accu-
rate, consistent reporting. Additionally, the binational TB case definition should enable
collaboration with Mexico’s programs and public health providers who might use a differ-
ent TB case definition than that used in the United States.
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Work Group Proposal
The work group defines a binational TB case as one that meets the U.S. or Mexican
case definition for active TB disease (21,22 ) plus one of the following criteria:
• Optimal case management requires communication or collaboration with TB
control programs or health-care providers on the opposite side of the border. For
example, a TB control program in the United States would transfer clinical or
laboratory data, refer a patient for treatment completion, or share information for
contact investigation with a Mexican TB control program.
• The case-patient is a contact of a binational TB case-patient or is the TB source
case-patient for contacts on the opposite side of the U.S.-Mexico border.
Registry of Binational TB Cases
U.S. TB control programs along the border identify locally defined binational cases in
their own TB registries, but none maintains local or statewide electronic records for
these cases. An electronic registry of binational TB cases available to all programs would
a) enhance documentation of the number of TB cases not included in the annual TB
morbidity count, b) facilitate sharing of up-to-date clinical data (e.g., prior anti-TB drug
treatment), and c) improve case management of binational TB cases.
Fundamental requirements for creating an electronic binational TB case registry are
a standard case definition and key database variables. Those key database variables
should reflect the unique characteristics of binational TB cases. Critical variables include
information regarding the frequency and duration of border crossings before and during
treatment, INS custody and disposition, anti-TB drug treatment regimen, drug resistance,
treatment using directly observed therapy, and beginning and ending treatment dates.
Creating a binational TB case database also requires decisions regarding
• responsibility for database development and maintenance,
• data validation and security,
• ability to link with other databases,
• ease of modification and updating,
• data analysis capability,
• report-generation capability,
• patient confidentiality, and
• cost.
The work group proposes the following three options for developing a unified registry
of binational TB cases:
• CDC’s TB Information and Management System (TIMS). TIMS is a
comprehensive software for surveillance, patient management, and program
evaluation that is used by U.S. state health departments to report TB surveillance
data to CDC. In each jurisdiction, TIMS can be adapted for local use as a registry of
binational TB cases via the user-defined variable option. Advantages include the
current availability of the system throughout the United States. Disadvantages
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include the necessary computer support, confidentiality, and the current
limitations to directly link TIMS with other jurisdictions in the United States;
however, indirect links are possible by using exported data sets from TIMS.
• Internet-based system. An Internet-based system, modeled on fully operational
existing systems (e.g., OpenEMed* [formerly TeleMed], which was developed by
Los Alamos National Laboratory and National Jewish Medical and Research
Center), could provide a secured database of binational TB case records available
for viewing and updating. Such a system would have advantages for following
and managing patients whose TB care spans multiple locations in the United
States and Mexico. An Internet-based system would require data security,
analytic capabilities, ability to link with existing databases, platform- and
operating-system independence, and users’ ability to access a secured Internet
site. Additional information is needed regarding feasibility, cost, maintenance,
data security, data integrity, and access to data in English and Spanish.
• Existing binational program databases. Electronic databases from existing
binational referral and follow-up programs could be used. CURE-TB and TB Net
are two such programs that have electronic databases, but they use different
software and formats. In addition, their primary function is patient follow-up and
management rather than surveillance.
Work Group Proposals
CDC should
• work with TB control programs in the United States and Mexico to a) verify the
need for a unified registry of binational TB cases; and b) determine if an existing
system could be modified for broader use and interfaced to reliably and securely
share information or if a new system should be developed.
• work with TB control programs, if developing a registry, to a) define the registry
variables, b) ensure data security and validation, and c) analyze registry data to
monitor case trends and identify populations at high risk.
• review current public health laws and clarify which surveillance data can be
shared among TB control programs in the United States and Mexico.
State and local TB control programs should
• collaborate with one another and CDC to determine a) the feasibility of creating
and maintaining a secure registry of binational TB cases, b) the sharing of
responsibilities for maintaining and updating the registry, and c) what would be
ideal mechanisms for data sharing, security, and use.
• collaborate with one another and CDC to determine a) the type of database
template to use, b) the primary function of the database (e.g., surveillance, case
management, or both), and c) key variables to be included. If an Internet-based
database is preferred, the collaborators should first assess users’ Internet-access
capabilities and the costs for ensuring Internet access for users of the surveillance
system.
* Information regarding OpenEMED is available at <http://www.acl.lanl.gov/TeleMed> (accessed
November 6, 2000).
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• consider adding variables to the locally defined fields in TIMS to identify and
follow trends among binational TB cases to facilitate data comparison among
jurisdictions.
• work with CURE-TB, TB Net, and other binational referral and follow-up systems
to avoid duplication of effort and improve case referral, follow-up, and
documentation of patients’ medical histories.
CASE MANAGEMENT AND THERAPY COMPLETION
Optimal TB case management includes prompt disease diagnosis, close monitoring
of medical regimens, assurance of adherence to treatment, and identification and evalu-
ation of close contacts. Each of these strategies becomes more difficult when case man-
agement must be coordinated among health jurisdictions, particularly across
international borders. Because the highest percentage of foreign-born TB patients living
in the United States comes from Mexico, shared case management could occur fre-
quently between the two countries. Coordination mechanisms should address differing
national case definitions, national protocols, priorities, and resources as well as cultural
and language differences. In the immediate U.S.-Mexico border area, case management
involves substantial numbers of persons moving across the border as often as daily. TB
patients who live on one side of the border might have their disease diagnosed or treated
in the adjacent country; therefore, investigation of close contacts often involves school,
work, and social settings on both sides of the border. Limited forums exist for disseminat-
ing information regarding successful case-management strategies across international
borders. Ongoing coordination among TB control programs in border areas is vital, and
local efforts to enhance these relationships should be encouraged.
Finding and Managing Active TB Cases
U.S. and Mexican citizens cross the border for TB diagnosis and treatment without
routinely notifying health departments of either country of their origin or destination.
Additionally, immigrants from Mexico and Central America who do not have documenta-
tion of citizenship or visas are not screened for active TB. Case management might be
compromised because of gaps and changes in treatment and failure to share clinical and
diagnostic information, perform timely contact investigations, and promote therapy
completion (23 ). Improved communication among TB agencies and health-care provid-
ers at local, state, national, and international levels is needed to ensure effective case
management and to coordinate care and completion of therapy.
Work Group Proposals
CDC should
• review privacy laws and clarify what case-specific information can be shared
among health departments and private health-care providers in the United States
and Mexico for providing clinical care.
• determine, for those Mexican and Central American immigrants identified during
immigration screening as possibly having TB, the number who complete their
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diagnostic evaluation and treatment. The number of legal immigrants who are
required or advised but fail to appear at the health department for testing and
evaluation should also be determined.
State and local TB control programs should
• develop new or strengthen existing partnerships with counterpart health
departments in Mexico to report and refer active TB case-patients and close
contacts who cross the U.S.-Mexico border for case management. Also,
procedures should be developed for referrals among U.S. and Mexican
nonborder TB control programs, including use of CURE-TB and TB Net.
• facilitate partnerships with health-care providers of TB patients on both sides of
the U.S.-Mexico border. Partnership agreements (e.g., memoranda-of-
understanding) should include timely reporting of active TB cases, treatment
outcome evaluations to improve completion of therapy, educational material
distribution, and training sessions for private health-care providers to improve
the recognition of TB symptoms and the evaluation of symptomatic persons.
Further, health-care providers along the U.S.-Mexico border should have current
guidelines for the care, treatment, and referral of active TB case-patients and for
seeking expert consultation for drug-resistant cases.
• document effective strategies that can be used in other communities for cross-
border notification of active TB case-patients and close contacts. These strategies
should be shared formally and informally at meetings or through publications and
the Internet.
• establish links with physicians (i.e., civil surgeons and panel physicians) who
evaluate immigration applicants and with community-based organizations
(CBOs) to conduct case-finding activities and provide information for those
persons in need of local TB services.
• develop and evaluate activities to inform communities and educate family
members of TB patients regarding the availability of local services and reevaluate
those activities regularly.
• identify potential barriers to establishing rapport with binational TB patients and
then develop case-management practices that actively address these barriers.
Funding To Provide Direct Services
TB control programs use their financial resources to provide services along the U.S.-
Mexico border. Certain U.S. health departments have memoranda-of-understanding with
Mexican health departments to provide diagnostic and therapeutic services in Mexico.
Other health departments provide services to Mexican TB patients in the United States
or facilitate co-management of patients who work or live on both sides of the border.
However, current Health Care Financing Administration (HCFA) regulations only permit
reimbursement for emergency care to persons without documentation of citizenship or
visas, but when these persons fail to complete TB treatment, the health of the U.S. public
is at risk. Ensuring treatment completion for active TB disease is a priority for TB control
programs. In addition, treatment of latent TB infection is cost-effective in reducing the
burden of disease and limiting future spread of TB infections (24 ).
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Work Group Proposals
CDC should
• work with border TB control programs to address case-management priorities
and ensure that activities are evaluated against established goals, objectives, and
outcomes. Border states will need guidance regarding federal funding sources for
TB case-management and program evaluation activities.
• collaborate with HCFA to explore amending Medicaid regulations to allow funding
for TB treatment to cure for persons without citizenship or visa documentation but
who otherwise would be eligible for Medicaid.
State and local TB control programs should
• emphasize technical assistance, quality improvement, and enhanced follow-up
and communication to co-manage binational patient care in their interactions with
Mexican counterparts.
Ensuring TB Patient Care While in INS Custody
In 1996, approximately 5 million immigrants were living in the United States without
documentation of citizenship or visas (25 ). As with legal immigrants, Mexico was the
leading country of origin for undocumented foreign-born immigrants, accounting for an
estimated 54% of the total number and 54% of the estimated annual increase (25 ).
Approximately 2 million immigrants were living in California without documentation of
citizenship or visas, and 700,000 more were living in Texas. In 1996, approximately
73,000 undocumented immigrants (73% from Mexico) were expelled through the judicial
process, and 1.6 million (99% from Mexico) were expelled through an INS procedure
known as “voluntary return under safeguards.” All such persons are detained in custody
under INS observation until their departure. Although the exact proportion of INS detain-
ees having TB is unknown, the rate of active TB disease among Mexican-born persons
without documentation of citizenship or visas could be higher than Mexico’s national
average. For example, at the Port Isabel, Texas, facility in 1998, 14 persons had active TB
disease, a rate of 116 cases/100,000 detainees, which is substantially higher than the
rate in Mexico (Abraham Miranda, M.D., personal communication, October 2000).
Because standard data regarding the disposition and outcomes of TB patients in INS
custody are not collected, the magnitude of this problem is unknown. In addition, the
majority of detainees are housed in local jails and state prisons, each of which has its own
TB screening policies and relationships with TB control programs. Detainees are trans-
ferred frequently between facilities, and certain facilities might not transfer medical
records containing TB status information.
Another barrier to TB patient care while in INS custody is the lack of communication
among TB control programs, federal agencies, and local and state facilities that house
INS detainees. Immigrants without documentation of citizenship or visas might be re-
leased to the community or deported to their country of origin without notification of
medical staff providing care to TB patients while in INS custody or the local health depart-
ment. Also, undocumented immigrants might return to the United States after release in
their country of origin. INS has no system for informing local TB programs regarding the
disposition of active or suspected TB cases. Resulting lapses in treatment can lead to
continued TB transmission and development of drug-resistant TB.
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Work Group Proposals
CDC should
• discuss the INS system, problems related to TB patients in INS custody, and areas
for collaboration with INS, USPHS/Division of Immigration Health Services, and
local, state, and federal correction agencies.
• clarify what case-specific information can be shared legally among health
departments, private health-care providers, and INS. Legalities of ensuring
completion of therapy by TB patients slated for exclusion or deportation should
also be determined by the legally responsible agencies.
• consult with USPHS/Division of Immigration Health Services regarding policies
and practices for TB case reporting; discharge planning, including notification of
Mexican consulates; continuity of care; and notification of local TB control
programs for community contact investigations for active and suspected TB
cases.
• work with INS to develop a system for monitoring and collecting data regarding
active and suspected TB patients in INS custody (e.g., number of cases identified,
length of treatment before release, drug-resistant TB, arrangements for ongoing
care, location of release, and rate of return to the United States). These data
should be shared with health departments.
State and local TB control programs should
• create liaisons with local INS officials to provide educational materials regarding
TB to personnel who work directly with detainees, ensure timely reporting of
active and suspected TB cases, establish referral systems to increase continuity
and completion of treatment, and provide medical consultation as needed.
• work with local facilities housing INS detainees to ensure that systems are in place
for identifying, isolating, and treating active and suspected TB patients.
• identify barriers to therapy completion after patients with active TB are released
from INS custody and assess the impact of measures to maintain continuity of TB
care among detainees or deportees.
• collaborate in developing Spanish-language materials that specify the locations
of local TB services, including binational TB referrals, that do not require
documentation of residence status and that state that confidentiality will be
maintained. These materials should be given to TB patients in INS custody and to
TB patients who do not have citizenship or visa documentation and are therefore
at risk for being detained by INS.
PERFORMANCE INDICATORS AND PROGRAM EVALUATION
Performance Indicator: TB Testing Among Border Populations
Unlike immigrants with citizenship or visa documentation, immigrants to the United
States from Mexico without such documentation are not screened upon entry for TB
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disease, human immunodeficiency virus (HIV) infection, and other health conditions that
influence the risk for progression from latent TB infection to active disease. Previously
uninfected immigrants from Mexico sometimes acquire latent TB infection after settling
in U.S. communities that have a high prevalence of TB. Targeted testing of specific popu-
lations at high risk is one strategy for finding and treating binational patients who arrive
in the United States with active TB disease or who are at risk for progression to active
disease (26,27 ). Priority groups for targeted testing and completion of treatment include
a) persons with HIV infection or other medical conditions (e.g., diabetes) that increase the
risk for active TB disease, b) medically underserved persons (e.g., incarcerated persons
or persons from areas of low socioeconomic status), and c) immigrants from Mexico who
have lived in the United States for <5 years (27 ). However, identifying, evaluating, and
treating to completion the close contacts of infectious TB patients should remain a higher




• assist in developing tools to evaluate the cost-effectiveness of targeted testing
programs.
• evaluate the usefulness of surveillance data and epidemiologic investigations for
defining populations in border communities with a high prevalence of latent TB
infection.
• develop an ethnographic and epidemiologic profile of persons at risk for TB,
investigate the health beliefs and care-seeking patterns of those at risk, and
define the patterns for TB transmission to other populations.
State and local TB control programs should
• evaluate outcomes for persons who have been started on treatment for latent TB
infection, stratified by ethnicity and place of birth.
• establish working relationships and formal memoranda-of-understanding with
providers who serve targeted populations (e.g., correctional facilities, managed
care organizations, HIV clinics, and migrant health clinics) to evaluate the
effectiveness of testing and treatment practices.
• seek partnerships with CBOs, schools, work sites, and others to evaluate and
improve the testing of recent immigrants and treatment-completion rates for
those person with active TB disease.
• train private providers who serve targeted populations regarding techniques of
tuberculin skin testing and educate them regarding the importance of appropriate
treatment for latent TB infection.
• inform communities of immigrants without documentation (e.g., through Spanish-
language community radio announcements) that persons who have or believe
they have active TB disease or latent TB infection can be evaluated and treated
with confidentiality.
18 MMWR January 19, 2001
Performance Indicator: Laboratory Support
Sharing laboratory data regarding binational TB patients whose disease was diag-
nosed in Mexico should be a critical component of case management for TB patients in
the United States. In addition, laboratory data for binational TB patients should be linked
with U.S. surveillance data. However, transfer of laboratory data among programs re-
quires a secure, confidential information system. Laboratory facilities in certain Mexican
border health departments lack the equipment and infrastructure to confirm diagnosis of
TB bacteriologically (cultures are not routinely performed by Mexican TB control pro-
grams along the border). Collaboration between Mexican and U.S. laboratories could
increase Mexico’s expertise in diagnosing TB disease and enhance their quality control.
Work Group Proposals
CDC should
• work with state and local TB control programs to develop key variables for
reporting laboratory data; these variables should be incorporated in the proposed
registry of binational TB cases.
• continue working with the Mexican National Public Health Laboratory Program
and U.S. and Mexican border states to build laboratory quality and proficiency
testing.
State and local TB control programs should
• seek opportunities, in collaboration with CDC, to strengthen TB diagnostic
capabilities in Mexican border states, with an emphasis on improving smear
microscopy and culture capability consistent with Mexican TB control policies.
Suggested support activities include improving quality control, training for
technicians, and identifying funding resources for equipment.
Performance Indicator: Contact Tracing
Contact tracing is a critical but complex component of identifying persons who have
active TB disease or who have latent TB infection and are at high risk for experiencing
active TB disease. Contact tracing for binational TB patients can be made even more
complex by a patient’s reluctance to divulge contacts, even to bicultural outreach work-
ers (28 ). Binational patients fear the stigma of disease and the possible social and legal
repercussions of a TB diagnosis (e.g., loss of housing, employment, and income or legal
action against persons without citizenship or visa documentation). Also, lack of experi-
ence with or understanding of preventive health models, cultural beliefs regarding causes
of TB other than a germ-based etiology, and self-medication approaches to treatment
(e.g., use of herbal products) might interfere with adherence to public health interventions (29 ).
Health-care providers and public health officials might be unsympathetic regarding
the problems of border-crossing patients, which can limit the effectiveness of contact
tracing. Further, TB contact investigators might lack training in necessary interviewing
skills for eliciting personal information from patients. Investigators might fail to under-
stand patients’ motivations, priorities in relation to a TB diagnosis, and adherence to
program guidance. Language and cultural barriers can hinder communication even fur-
ther. Lack of understanding of the social patterns of binational patients can impede con-
tact tracing. As a result, the traditional contact-tracing concentric-circle model (30 ) might
not be effective in identifying close contacts because of differing social patterns. Defi-
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ciencies in communication among public health jurisdictions can hinder contact investi-
gations, especially if coordination must span international borders. Finally, protocols for
contact tracing differ between the United States and Mexico (22,31,32 ).
Work Group Proposals
CDC should
• develop, in conjunction with state and local TB control programs, standardized,
linguistically and culturally appropriate contact interview questions intended to
elicit contact information regarding cross-border social networks and extended
family structures.
• work with state and local health departments to develop a culturally sensitive
interview training program for TB contact investigators. Training programs
should emphasize principles of reflective listening (33–35 ), and their content
should be based on studies of hard-to-reach populations.
• support a sociobehavioral study of binational TB patients’ priorities, motivations,
and expectations, and the ways in which these affect adherence to recommended
TB evaluation and treatment. Key issues include binational patients’ experience
with health care in their country of origin and in the United States, reasons for
moving to the United States, and perceptions regarding government agencies.
State and local TB control programs should
• work with CDC on projects designed to enhance the understanding of TB patients’
culture, experiences, opinions, motivations, and concerns.
• designate a liaison to work with other jurisdictions in coordinating contact
investigations across state and international borders, within a context of differing
protocols and policies in Mexico. The usefulness of patient interviews in the
United States to identify close contacts in Mexico should be evaluated.
• collaborate with CBOs that serve binational TB patients to determine if techniques
used in other screening programs (e.g., use of nonprofessional community health
workers as liaisons and educators) could enhance contact tracing.
• seek to benefit from other public health programs in understanding the social
networks in the community and to acquire new, more effective interview
techniques.
Program Evaluation
Performance of TB control programs among binational populations has not been
characterized adequately in terms of prevention and treatment interventions because
program evaluation requires sharing the three performance indicators as discussed
previously. These indicators should be based on a hierarchy of programmatic goals:
a) measurable outcomes of TB diagnosis and treatment for persons with active disease,
b) efficient processes for ensuring the completion of treatment of persons with TB, and
c) adequate infrastructure for the system that delivers TB services.
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Work Group Proposals
CDC should
• work with local, state, and federal agencies with expertise in TB control and
program evaluation to agree on and disseminate a framework for program
evaluation designed explicitly for binational TB cases. Specific performance
indicators should correlate with the priority goals and activities identified during
that process.
• evaluate state-based and other binational TB control programs, including
binational referral and follow-up systems, by applying the performance indicators
included in the evaluation framework.
• assist in devising tools for evaluating contact investigations of binational cases
and determine the operational outcomes and cost-effectiveness of expanding
contact investigations beyond close contacts.
State and local TB control programs should
• develop and share instruments for collecting data regarding program
performance indicators and set objectives on the basis of those indicators. Pilot
testing of the indicators to determine their usefulness and validity would be
needed during the development process.
• use program performance indicators and the evaluation framework, including
indicators based on standards of practice, to document needed resources.
RESEARCH NEEDS
Identifying Strategies To Eliminate TB Disease
As TB incidence declines in the United States, public health strategies must extend
beyond traditional TB control measures to activities that will eliminate TB disease (31 ).
These strategies should include active case finding, targeted testing and treatment of
populations at high risk for latent TB infection, and promotion of regional TB control
efforts along the U.S.-Mexico border. Despite advances made during the 1990s, applied
public health research is needed to identify the best strategies for eliminating TB disease.
Applied research to improve TB control efforts along the U.S.-Mexico border must
address two groups distinguished by their pattern of movement and the health-care
systems that serve them. The first group consists of binational patients and their close
contacts for whom recent or ongoing cross-border travel affects case management,
contact tracing, and source-case investigation. The second group consists of patients
who acquired TB in Mexico or Central America, and their contacts in the United States,
whose case management is less complicated by international travel, but who might
migrate between jobs in the service, construction, and agricultural industries in defined
patterns in the United States (Figure 3). This group might benefit from targeted testing
and treatment for latent TB infection. For example, during the early 1990s, among
Mexican-born persons seeking adjustment of their residency status in Denver, Colorado,
an estimated 40% had tuberculin skin tests indicating that they had latent TB infection,
compared with an estimated 4% of the U.S. population (36 ).
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Work Group Proposals
CDC should
• assist state and local TB control programs in analyzing surveillance data and
conducting studies to identify trends, opportunities, and knowledge gaps related
to binational TB patients.
• advise policy makers, public health program personnel, researchers, funding
organizations, and others regarding priorities for public health research on
binational TB cases in the context of the national TB prevention and control
program.
FIGURE 3. Migration patterns in the United States among workers originating from
Mexico
Source: Adapted from Migrant Clinicians Network. Austin, TX: Migrant Clinicians Network,
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• assist researchers in minimizing duplication and encourage immediate, effective
developments in applied public health research regarding TB.
State and local TB control programs should
• increase use of local data and experience to advise CDC and state and local
authorities regarding the epidemiology of TB among binational populations,
practical problems in TB control, and emerging situations that might require
attention or action.
• evaluate the efficiency of TB prevention and control activities and update
performance indicators as needed.
• in collaboration with health-care providers, define the contributions of
subpopulations to TB morbidity in their jurisdictions. The role of congregate
settings (e.g., correctional institutions, shelters, dormitories, migrant worker
camps, and hospitals) in facilitating TB transmission among these populations
should also be assessed.
Areas for Additional Research
• Binational TB case surveillance. Although national surveillance data have
included ethnicity since 1980 and country of origin since 1993, these variables do
not capture the information needed to determine whether a TB case could be
classified as binational. Furthermore, data are not collected routinely regarding
the movement of TB patients to, from, or within Mexico, except for the date of
entry into the United States. Therefore, determining the problem’s magnitude,
contributions of different groups, or relative risk attributable to specific risk
factors is not possible. Without this information, assessing the burden of TB
disease by geographic region and targeting prevention and control efforts
accordingly is inefficient.
• Delayed treatment. Rapid disease diagnosis and prompt initiation of treatment
are critical in curbing TB transmission within the community. Anecdotal evidence
based on clinical experience implies that binational patients’ disease is diagnosed
and treated at more advanced stages of illness than that of other patients. Such
patients might visit two or more health-care providers before treatment is
started. Research is needed to determine the true frequency of these cases and,
if elevated, to identify the risk factors.
• Treatment completion. Mobility of binational patients within the United States
and bilaterally across the U.S.-Mexico border complicates the continuity of
treatment and decreases the rate of treatment completion. Only limited data
regarding the outcomes of binational cases and the factors that contribute to
satisfactory outcomes have been published (23,37,38 ). Also unclear is the extent
to which resources should be directed toward developing and evaluating
methods to ensure that treatment is completed. Without this knowledge, methods
are unreliable for determining a) which aspects of the clinical and public health
management of binational TB cases are beneficial, b) which aspects should be
encouraged, and c) which aspects should be improved, modified, or abandoned.
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• Drug resistance. Limited data regarding drug resistance among Mexican TB
patients in both countries have been published (18,39,40 ). Clinicians who serve
TB patients from Mexico report high levels of drug resistance, but no clearly
defined, population-based data have been compiled to determine the incidence or
prevalence of drug-resistant TB among binational patients. Moreover, only
recently has Mexico adopted standards for retreating patients and started
promoting directly observed therapy. Research is needed to determine levels of
drug resistance and risk factors contributing to drug resistance among TB patients
from Mexico.
• Contact investigation. Mexican policies and practices for contact tracing differ
from those of the United States, and thorough contact tracing, testing, and
treatment of latent infection might be difficult or impossible in foreign
jurisdictions. Highly mobile patients might have contacts in multiple locations in
the United States, complicating the identification, testing, and treatment of
latently infected persons as well (Figure 4). Data are needed to quantify the extent
to which these considerations affect binational populations (41,42 ). Information
regarding the cost-effectiveness of contact tracing would enable efforts to be
directed effectively.
FIGURE 4. Movement of selected TB cases enrolled in TB Net, 1997–1998
Source: Migrant Clinician Network. Austin, TX: Migrant Clinicians Network, 2000. Available at
<http://www.migrantclinician.org>. Accessed November 21, 2000.
3
1. Denver, Colorado–El Paso, Texas–Denver, Colorado
2. Salem, Oregon–Vera Cruz, Mexico
3. McAllen, Texas–Traverse City, Michigan –McAllen, Texas 
4. Bear Lake, Michigan–Bowling Green, Florida–Edinburg, Texas–Bear Lake, Michigan
5. Odessa, Texas–Tyler, Texas –Odessa, Texas–El Paso, Texas–Delicias, Chihuahua
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• Targeted testing. Foreign-born residents and visitors from countries having a
high incidence of TB, including Mexico and Central America, can be at risk for
latent TB infection or active TB disease. With the exception of the required
radiologic screening of applicants for immigrant visas and for adjustment of
immigration status (43 ), no systematic procedures have been applied to test
foreign-born persons for latent TB infection. Although certain approaches have
been attempted at the local level, conclusive cost-outcome or cost-effectiveness
data are limited (36,44,45 ). Therefore, how best to target binational populations
for testing and treatment of latent infection is unknown as is reaching subgroups
who might provide opportunities for TB prevention and ensuring completion of
treatment (46 ). Historically, treatment-completion rates for latent TB infection
have been lower than for active TB disease, making necessary the reassessment
of existing strategies for treatment of latent TB infection. Evaluating which
strategies are cost-effective will be critical.
Work Group Proposals
CDC should
• work with state and local TB control programs to determine the extent to which
reported TB morbidity in the United States originates in Mexico and Central
America by focusing on geographic areas and populations that have high rates of
binational TB cases.
• collaborate with state and local TB control programs to assess and quantify
delays in completing treatment and factors that contribute to delays.
• work with state and local TB control programs to determine the magnitude and
impact of mobility among binational patients on treatment completion and health
outcomes.
• determine the epidemiology of drug-resistant TB among binational patients.
State and local TB control programs should
• collaborate with public health and social scientists to develop and evaluate
innovative methods for tracing, testing, and treating contacts of binational
patients. Studies should compare new strategies with past practices.
• in accordance with new CDC guidelines for targeted testing and treatment of
latent infection (47 ), a) develop methods to identify persons at high risk for TB
who would benefit from treatment of latent TB infection, if detected; b) test these
persons for latent TB infection; and c) treat to completion latently infected
persons. Identifying persons at risk for latent TB infection could be done on the
basis of local epidemiologic profiles or other methods. Cost and outcomes or
effectiveness of strategies should be assessed as an integral component of this
research.
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GOAL AND OBJECTIVES
This MMWR  describes the burden of binational tuberculosis (TB) among U.S.-Mexico border populations and
reports on findings and proposals from the work group. The goal of this report is to guide local, state, and federal
public health officials, nongovernmental organizations and agencies, and practitioners in devising interventions to
decrease TB morbidity found among migratory populations originating in Mexico and Central America. Upon
completion of this educational activity, the reader should be able to a) describe the burden of tuberculosis among
populations along the U.S.-Mexico border; b) identify specific needs for improving surveillance, case
management, program evaluation, and research for binational TB cases; and c) identify approaches to
collaboration among health departments, nongovernmental organizations, and Mexican health officials.
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1. One factor that contributes to an elevated TB incidence in U.S. border counties is . . .
A. improved access to health care in the border area.
B. infrequent border crossings by U.S. citizens.
C. lack of coordinated care across health jurisdictions on both sides of the U.S.-Mexico
border.
D. lower TB case rates in Mexico.
2. Critical research areas for improving TB prevention and control along the U.S.-Mexico
border include . . .
A. frequency of, reasons for, and strategies to prevent delayed diagnosis and treatment
of TB among binational patients.
B. the impact of mobility within the U.S. and across the border on completion of
treatment and on treatment outcomes.
C. prevalence of specific patterns of resistance to anti-TB drugs among binational TB
patients.
D. all of the above are critical research areas.
3. Which of the following statements is true?
A. Anti-TB drug resistance rates among U.S.-born TB patients are generally higher than
among Mexican-born TB patients.
B. Mexican-born TB patients live in the United States for a shorter time before diagnosis
than persons born in other countries.
C. Therapy completion rates for U.S.-born and Mexican-born TB patients are
comparable.
D. Approximately 75% of Mexican-born TB patients have evidence of cavitary disease
on chest radiographs.
4. Which of the following statements is true?
A. A computerized registry of all binational TB cases currently exists in Arizona,
California, New Mexico, and Texas.
B. A binational TB registry would enhance surveillance and documentation of the TB
case burden along the U.S.-Mexico border.
C. TIMS and the Internet are the best options for developing a binational TB case
registry.
D. Databases for CURE-TB and TB Net currently use the same formats and can be linked
easily.
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5. What is an essential component of binational TB case management?
A. Prompt diagnosis of latent TB infection.
B. Identifying and evaluating all contacts.
C. Providing free medications that are self-administered.
D. Ensuring adherence to curative therapy.
6. Which of the following factors compromises optimal co-management of patients with
active TB and their contacts in the United States and Mexico?
A. Lack of communication between TB control agencies and health-care providers at
local, state, national, and international levels.
B. Sharing confidential clinical and diagnostic information.
C. Using bilingual and bicultural outreach workers to perform contact investigations.
D. Using standard treatment protocols.
7. Which of the following is a barrier to ensuring appropriate care for patients with active
TB while in Immigration and Naturalization Service (INS) custody?
A. Having an effective communication system among local TB control programs, the
U.S. Public Health Service’s Division of Immigration Health Services, INS and other
Department of Justice agencies, and domestic facilities where INS detainees are
held.
B. Releasing immigrants who do not have citizenship or visa documentation into the
community or returning them to their country of origin without notification of the
appropriate health-care providers.
C. Having a systematic mechanism to inform local TB control programs regarding the
disposition and outcomes of active and suspected TB cases.
D. Housing INS detainees in single-room–occupancy hotels or shelters.
8. Laboratory support for controlling TB along the U.S.-Mexico border should include all of
the following except . . .
A. linking laboratory data with U.S. TB surveillance data.
B. collaboration between Mexican and U.S. laboratories to enhance Mexico’s quality
control.
C. performing sensitivity testing on all isolates from TB patients on the Mexican side of
the border.
D. identifying resources for building the infrastructure of laboratories in the border
states.
9. Whick factor is most important when considering testing and treating border
populations for latent TB infection?
A. Unlike immigrants with citizenship or visa documentation, immigrants to the United
States from Mexico without such documentation are not screened upon entry for TB
disease.
B. Immigrants from Mexico without TB infection sometimes acquire active TB infection
after settling in U.S. communities.
C. Priority groups include immigrants from Mexico who have lived in the United States
for <5 years.
D. The first priority is identifying, evaluating, and treating to completion the close
contacts of infectious TB patients; therefore, contact investigation has priority over
targeted testing of populations at risk.
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10. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
11. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.




12. I plan to use these recommendations as the basis for . . . (Indicate all that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.







14. How much time did you spend reading this report and completing the exam?
A. 0.5–1.0 hour.
B. More than 1.0 hour but fewer than 1.5 hours.
C. More than 1.5 hours but fewer than 2 hours.
D. More than 2.0 hours but fewer than 2.5 hours.
E. More than 2.5 hours.
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15. After reading this report, I am confident I can describe the burden of tuberculosis among
populations along the U.S.-Mexico border.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can identify specific needs for improving




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can identify approaches to collaboration




C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. The tables and figures are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–9
1. C; 2. D; 3. C; 4. B; 5. D; 6. A; 7. B; 8. C; 9. D.
20. Overall, the presentation of the report enhanced my ability to understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. How did you learn about this continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, MMWR  cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. MMWR  subscription.
F. Other.
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